Effect of transferrin on hypomyelination induced by iron deficiency.
We have used a model of iron deficiency in the rat to analyze the effects of a disruption in iron availability on oligodendroglial cell (OLGc) maturation and myelinogenesis and to explore the possible beneficial influence of an intracranial injection (ICI) of apotransferrin (aTf) at 3 days of age on this process. Studies carried out on postnatal days 17 and 24 showed that iron deficiency produced a decrease in myelin proteins and lipids at 24 days of age. Immunohistochemistry showed that in untreated iron-deficient (ID) rats, the immunoreactivity of anti-adenomatous polyposis coli (APC) and anti-MBP antibodies decreased markedly with reference to normal controls, whereas in ID rats treated with an ICI of aTf, the immunoreactivity of these markers increased. A similar situation occurred with the immunoreactivity of H-ferritin. In primary OLGc cultures from ID rats, there was a high number of cells positive to the antibody against the polysialylated form of the cell surface glycoprotein NCAM (PSA-NCAM) compared with in OLGc cultures prepared from normal controls or from ID animals treated with aTf. The number of MBP+ cells in cultures from ID rats increased after treatment with aTf. The presence of lipid rafts evaluated with a specific anti-protein prion cellular (PrPc) antibody showed a smaller number of PrPc-positive structures in ID rat cultures. Treatment of the ID animals with a single ICI of aTf stimulated myelination, producing a significant correction in the different biochemical parameters affected by ID.
Badaracco
M E
ME
Instituto de Química y Fisicoquímica Biológica (IQUIFIB) UBA-CONICET and Departamento de Química Biológica, Facultad de Farmacia y Bioquímica, Buenos Aires, Argentina.
Ortiz
E H
EH
Soto
E F
EF
Connor
J
J
Pasquini
J M
JM
D018798:Anemia, Iron-Deficiency / Q000097:blood / Q000188:drug therapy* / Q000473:pathology*; D000818:Animals; D000831:Animals, Newborn; D001059:Apoproteins / Q000494:pharmacology / Q000627:therapeutic use*; D002478:Cells, Cultured; D003711:Demyelinating Diseases / Q000097:blood / Q000188:drug therapy* / Q000473:pathology*; D004195:Disease Models, Animal; D005260:Female; D009186:Myelin Sheath / Q000187:drug effects / Q000473:pathology; D009413:Nerve Fibers, Myelinated / Q000187:drug effects / Q000473:pathology*; D011247:Pregnancy; D051381:Rats; D017208:Rats, Wistar; D014168:Transferrin / Q000494:pharmacology / Q000627:therapeutic use*
D001059:Apoproteins; D014168:Transferrin; C028284:apotransferrin